Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis

Clicks: 344
ID: 268471
2017
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
clinicaltrials.gov Identifiers: NCT02243280 and NCT02243293. http://www.clinicaltrials.gov/show/NCT02243280, http://www.clinicaltrials.gov/show/NCT01939197.
Reference Key
py2017journalglecaprevir Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Kwo PY;Poordad F;Asatryan A;Wang S;Wyles DL;Hassanein T;Felizarta F;Sulkowski MS;Gane E;Maliakkal B;Overcash JS;Gordon SC;Muir AJ;Aguilar H;Agarwal K;Dore GJ;Lin CW;Liu R;Lovell SS;Ng TI;Kort J;Mensa FJ;;
Journal journal of hepatology
Year 2017
DOI DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/28412293
Keywords
hepatitis c National Center for Biotechnology Information NCBI NLM MEDLINE genetic humans pubmed abstract nih national institutes of health national library of medicine adult female male aged middle aged Drug Administration Schedule Clinical Trial Multicenter Study Genotype Polymorphism drug resistance multiple drug therapy combination ribavirin / administration & dosage phase ii viral / genetics antiviral agents / adverse effects hepacivirus / genetics* chronic / drug therapy* antiviral agents / administration & dosage* ribavirin / adverse effects treatment failure fred poordad hepacivirus / drug effects sustained virologic response Quinoxalines / adverse effects benzimidazoles / administration & dosage* pmid:28412293 doi:10.1016/j.jhep.2017.03.039 paul y kwo federico j mensa benzimidazoles / adverse effects chronic / virology* pyrrolidines / administration & dosage* pyrrolidines / adverse effects quinoxalines / administration & dosage* sulfonamides / administration & dosage* sulfonamides / adverse effects

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.